Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and Radiation in Metastatic MSS Pancreatic Cancer
NCT04361162Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab, sponsored by Massachusetts General Hospital. Primary endpoint: Overall Response Rate at 6 weeks. Started May 2020; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
Beyond the preview
Go deeper on NCT04361162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361162.